alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 23 

 

Consent of Independent Registered Public Accounting Firm 

 

The Board of Directors 

ViroPharma Incorporated: 

 

We consent to theincorporation by reference in the registration statements (No. 333-34129, No. 333-38248, No. 333-60951, No. 333-38256 and No. 333-109600) on Form S-8 and the registration statements (No. 333-37960, No. 333-64482, No. 333-99533 and 333-122315) onForm S-3 of ViroPharma Incorporated of our report dated March 11, 2005, with respect to the consolidated balance sheets of ViroPharma Incorporated and subsidiary as of December 31, 2004 and 2003, and the related consolidated statements ofoperations, comprehensive loss, stockholders’ equity (deficit) and cash flows for each of the years in the three-year period ended December 31, 2004, which report appears in the December 31, 2004. Annual Report on Form 10-K of ViroPharmaIncorporated. 

 

/s/ KPMG LLP 

 

Philadelphia, Pennsylvania 

March 11, 2005
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.3800 Automated slide stainer. ( a ) *Identification.* An automated slide stainer is a device used to stain histology, cytology, and hematology slides for diagnosis.
( b ) *Classification.* Class I (general controls). This device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
[45 FR 60591, Sept. 12, 1980, as amended at 54 FR 25044, June 12, 1989; 66 FR 38789, July 25, 2001]
§ 530.3 Definitions. ( a ) *Extralabel use* means actual use or intended use of a drug in an animal in a manner that is not in accordance with the approved labeling. This includes, but is not limited to, use in species not listed in the labeling, use for indications (disease or other conditions) not listed in the labeling, use at dosage levels, frequencies, or routes of administration other than those stated in the labeling, and deviation from the labeled withdrawal time based on these different uses.
( b ) *FDA* means the U.S. Food and Drug Administration.
( c ) The phrase *a reasonable probability that a drug's use may present a risk to the public health* means that FDA has reason to believe that use of a drug may be likely to cause a potential adverse event.
( d ) The phrase *use of a drug may present a risk to the public health* means that FDA has information that indicates that use of a drug may cause an adverse event.
( e ) The phrase *use of a drug presents a risk to the public health* means that FDA has evidence that demonstrates that the use of a drug has caused or likely will cause an adverse event.
( f ) A *residue* means any compound present in edible tissues that results from the use of a drug, and includes the drug, its metabolites, and any other substance formed in or on food because of the drug's use.
( g ) A *safe level* is a conservative estimate of a drug residue level in edible animal tissue derived from food safety data or other scientific information. Concentrations of residues in tissue below the safe level will not raise human food safety concerns. A safe level is not a safe concentration or a tolerance and does not indicate that an approval exists for the drug in that species or category of animal from which the food is derived.
( h ) *Veterinarian* means a person licensed by a State or Territory to practice veterinary medicine.
( i ) A *valid veterinarian-client-patient relationship* is one in which: ( 1 ) A veterinarian has assumed the responsibility for making medical judgments regarding the health of (an) animal(s) and the need for medical treatment, and the client (the owner of the animal or animals or other caretaker) has agreed to follow the instructions of the veterinarian;
( 2 ) There is sufficient knowledge of the animal(s) by the veterinarian to initiate at least a general or preliminary diagnosis of the medical condition of the animal(s); and
( 3 ) The practicing veterinarian is readily available for followup in case of adverse reactions or failure of the regimen of therapy. Such a relationship can exist only when the veterinarian has recently seen and is personally acquainted with the keeping and care of the animal(s) by virtue of examination of the animal(s), and/or by medically appropriate and timely visits to the premises where the animal(s) are kept.
Exhibit 32.1Certification Pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934     In connection with the quarterly report on Form 10-Q of Youbet.com, Inc. (the “Company”) forthe period ended June 30, 2006, as filed with the Securities and Exchange Commission as of the datehereof (the “Report”), I, Charles F. Champion, Chief Executive Officer of the Company, and I, GaryW. Sproule, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:     (1) the Report fully complies with the requirements of Section 13(a) of the SecuritiesExchange Act of 1934, as amended; and     (2) the information contained in the Report fairly presents, in all material respects, thefinancial condition and results of operations of the Company.       August 9, 2006 By: /s/ Charles F. Champion            Charles F. Champion      President and Chief Executive Officer         August 9, 2006 By: /s/ Gary W. Sproule            Gary W. Sproule      Chief Financial Officer and Treasurer  A signed original of this written statement required by Section 906, or other documentationauthenticating, acknowledging, or otherwise adopting the signature that appears in typed formwithin the electronic version of this written statement required by Section 906, has been providedto the Company and will be retained by Youbet.com, Inc. and furnished to the Securities andExchange Commission or its staff upon request.This certification “accompanies” the quarterly report on Form 10-Q to which it relates, is notdeemed filed with the Securities and Exchange Commission, and is not to be incorporated byreference into any filing of the Company under the Securities Act of 1933, as amended, or theSecurities Exchange Act of 1934, as amended (whether made before or after the date of the quarterlyreport on Form 10-Q, irrespective of an general incorporation language contained in such filing).
§ 520.110 Apramycin sulfate soluble powder. ( a ) *Specifications.* A water soluble powder used to make a medicated drinking water containing apramycin sulfate equivalent to 0.375 gram of apramycin activity per gallon of drinking water.
( b ) *Sponsor.* See No. 058198 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.52 of this chapter.
( d ) *Conditions of use in swine* — ( 1 ) *Amount.* Administer in drinking water at the rate of 12.5 milligrams of apramycin per kilogram (5.7 milligrams per pound) of body weight per day for 7 days.
( 2 ) *Indications for use.* For the control of porcine colibacillosis (weanling pig scours) caused by strains of *Escherichia coli* sensitive to apramycin.
( 3 ) *Limitations.* Do not slaughter treated swine for 28 days following treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[47 FR 15771, Apr. 13, 1982, as amended at 49 FR 19642, May 9, 1984; 53 FR 37753, Sept. 28, 1988; 79 FR 28818, May 20, 2014; 81 FR 48702, July 26, 2016; 81 FR 94989, Dec. 27, 2016]
RULE 13a-14(a)/15d-14(a) CERTIFICATION

I, Richard Dea, Chief Financial Officer, certify that:

1.	I have reviewed this quarterly report on Form 10-QSB of InZon
Corporation (formerly W-J International, Ltd.);

2.	Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect
to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all
material respects the financial condition, results of operations and
cash flows of the small business issuer as of, and for, the periods
presented in this report;

4.	I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) [omitted pursuant to extended compliance period] for
the small business issuer and have:

(a) Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating
to the small business issuer, including its consolidated
subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report
is being prepared;

(b)  [omitted pursuant to extended compliance period]

(c) Evaluated the effectiveness of the small business issuer's
disclosure controls and procedures and presented in this report
our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by
this report based on such evaluation; and

(d) Disclosed in this report any change in the small business
issuer's internal control over financial reporting that
occurred during the small business issuer's most recent fiscal
quarter (the small business issuer's fourth fiscal quarter in
the case of an annual report) that has materially affected, or
is reasonably likely to materially affect, the small business
issuer's internal control over financial reporting; and

5.	I have disclosed, based on my most recent evaluation of
internal control over financial reporting, to the small business
issuer's auditors and the audit committee of the small business
issuer's board of directors (or persons performing the equivalent
functions):

(a) All significant deficiencies and material weaknesses in the
design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the
small business issuer's ability to record, process, summarize
and report financial information; and

(b) Any fraud, whether or not material, that involves
management or other employees who have a significant role in
the small business issuer's internal control over financial
reporting.


Dated: May 21, 2006                 By: /s/ Richard Dea
                                        ----------------
		 		    	Richard Dea,
                                        Chief Financial Officer



<PAGE>
#### The Hartford Electric Light Company *v.*Water Resources Commission et al.

Submitted October 1

decided October *10,*1968

The petition by Julian D. Rosenberg for leave to file a brief and to argue before this court as amicus curiae in the appeal from the Superior Court in Hartford County is granted to the extent that permission is granted to file a brief as amicus curiae.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF LOGAN'S ROADHOUSE, INC. FOR THE FISCAL YEAR ENDED
DECEMBER 29, 1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS INCLUDED IN LOGAN'S ROADHOUSE, INC'S. ANNUAL REPORT ON
FORM 10-KSB.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-29-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-29-1996
<CASH>                                         780,307
<SECURITIES>                                 9,060,733
<RECEIVABLES>                                  353,250
<ALLOWANCES>                                         0
<INVENTORY>                                    250,582
<CURRENT-ASSETS>                            10,442,008
<PP&E>                                      35,553,402
<DEPRECIATION>                               1,861,628
<TOTAL-ASSETS>                              45,459,099
<CURRENT-LIABILITIES>                        4,809,238
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        60,138
<OTHER-SE>                                  39,941,695
<TOTAL-LIABILITY-AND-EQUITY>                45,459,099
<SALES>                                     41,044,121
<TOTAL-REVENUES>                            41,044,121
<CGS>                                       32,717,767
<TOTAL-COSTS>                               32,717,767
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              69,606
<INCOME-PRETAX>                              6,310,558
<INCOME-TAX>                                 2,161,997
<INCOME-CONTINUING>                          4,148,561
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 4,148,561
<EPS-PRIMARY>                                     0.71
<EPS-DILUTED>                                     0.71


</TABLE>
#### Charles LoDolce et al. *v.*Town Plan Commission of the Town of Newington

*Arnold E. Buchman,*for the appellant (named plaintiff).

*Steven E. Perakos,*for the appellant (plaintiff Anthony L. LaMont).

*William V. Dworski,*for the appellee (defendant).

Argued December 2

decided December 2, 1969

It appearing that the plaintiffs in the above-entitled case have failed to prosecute their appeal from the Court of Common Pleas in Hartford County with proper diligence, it is, under Practice Book § 696, ordered by the Supreme Court, suo motu, that the appeal be and hereby is dismissed.
Docket No. FAA-2012-0270
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.7400 Hemoglobin A2 assay. ( a ) *Identification.* A hemoglobin A2 assay is a device used to determine the hemoglobin A2 content of human blood. The measurement of hemoglobin A2 is used in the diagnosis of the thalassemias (hereditary hemolytic anemias characterized by decreased synthesis of one or more types of hemoglobin polypeptide chains).
( b ) *Classification.* Class II (performance standards).
[45 FR 60617, Sept. 12, 1980]
* Pursuant to 5 TH C IR . R. 47.5, the court has determined

that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. United States Court of Appeals Fifth Circuit 

## FILED August 20, 2003 Charles R. Fulbruge III Clerk IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 03-40155 Conference Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus RAFAEL JAIMES-ARANDA, also known as Justantino Sanchez-Aranda, Defendant-Appellant.

-------------------- Appeal from the United States District Court for the Southern District of Texas USDC No. B-02-CR-554-1

-------------------- Before JONES, WIENER, and BENAVIDES, Circuit Judges.
PER CURIAM: * Rafael Jaimes-Aranda appeals the sentence imposed following his guilty plea conviction of being found in the United States after deportation/removal in violation of 8 U.S.C. § 1326. Jaimes-Aranda complains that his sentence was improperly enhanced pursuant to 8 U.S.C. § 1326(b) based on a prior conviction. He argues that the sentencing provision is unconstitutional. Jaimes-Aranda thus contends that his sentence should not exceedNo. 03-40155 -2- the maximum terms of imprisonment prescribed in 8 U.S.C. § 1326(a).
In Almendarez-Torres v. United States , 523 U.S. 224, 235 (1998), the Supreme Court held that the enhanced penalties in 8 U.S.C. § 1326(b) are sentencing provisions, not elements of separate offenses. The Court further held that the sentencing provisions do not violate the Due Process Clause. Id. at 239-47. Jaimes-Aranda acknowledges that his argument is foreclosed by Almendarez-Torres , but asserts that the decision has been cast into doubt by Apprendi v. New Jersey , 530 U.S. 466, 490 (2000). He seeks to preserve his argument for further review. Apprendi did not overrule Almendarez-Torres
. See Apprendi , 530 U.S. at 489-90; United States v. Dabeit , 231 F.3d 979, 984 (5th Cir. 2000). This court must follow Almendarez-Torres “unless and until the Supreme Court itself determines to overrule it.” Dabeit , 231 F.3d at 984 (internal quotation marks and citation omitted). The judgment of the district court is
AFFIRMED. The Government has moved for a summary affirmance in lieu of filing an appellee’s brief. In its motion, the Government asks that an appellee’s brief not be required. The motion is GRANTED.
AFFIRMED; MOTION GRANTED.
# C_2014421EN.01006201.xml

| 24.11.2014 | EN | Official Journal of the European Union | C 421/62 |
| --- | --- | --- | --- |

24.11.2014

EN

Official Journal of the European Union

C 421/62

---

Action brought on 26 August 2014 — ZZ and Others v Commission

(Case F-85/14)

2014/C 421/90

Language of the case: French

Parties

Parties

Applicant: ZZ and Others (represented by: S. Orlandi, lawyer)

Applicant:

Defendant: Commission

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Inapplicability of Article 7 of Annex V and Article 8 of Annex VII of the Staff Regulations, as amended by Regulation No 1023/2013 of the European Parliament and of the Council of 22 October 2013 amending the Staff Regulations and the CEOS and annulment of the decisions withdrawing the reimbursement of travel expenses from the place of employment to the place of origin and abolishing travelling time.

Form of order sought

Form of order sought

| — | Declare Article 7 of Annex V of the Staff Regulations and Article 8 of Annex VII of the Staff Regulations unlawful; |
| --- | --- |

—

Declare Article 7 of Annex V of the Staff Regulations and Article 8 of Annex VII of the Staff Regulations unlawful;

| — | annul the decision not to grant any further travelling time or reimbursement of annual travel expenses to the applicants, from the year 2014 onwards; |
| --- | --- |

—

annul the decision not to grant any further travelling time or reimbursement of annual travel expenses to the applicants, from the year 2014 onwards;

| — | order the Commission to pay the costs. |
| --- | --- |

—

order the Commission to pay the costs.

---
§ 640.2 General requirements. ( a ) *Manufacturing responsibility.* All manufacturing of Whole Blood, including donor examination, blood collection, laboratory tests, labeling, storage and issue, shall be done under the supervision and control of the same licensed establishment except that the Director, Center for Biologics Evaluation and Research, may approve arrangements, upon joint request of two or more licensed establishments, which he finds are of such a nature as to assure compliance otherwise with the provisions of this subchapter.
( b ) *Blood container.* The blood container shall not be entered prior to issue for any purpose except for blood collection or when the method of processing requires use of a different container. The container shall be uncolored and transparent to permit visual inspection of the contents and any closure shall be such as will maintain a hermetic seal and prevent contamination of the contents. The container material shall not interact with the contents under the customary conditions of storage and use, in such a manner as to have an adverse effect upon the safety, purity, or potency of the blood.
( c ) *Reissue of blood.* Blood that has been removed from storage controlled by a licensed establishment shall not be reissued by a licensed establishment unless the following conditions are observed: ( 1 ) The container has a tamper-proof seal when originally issued and this seal remains unbroken;
( 2 ) A segment is properly attached and has not been removed, except that blood lacking a properly attached segment may be reissued in an emergency provided it is accompanied by instructions for sampling and for use within 6 hours after entering the container for sampling;
( 3 ) The blood has been stored continuously at 1 to 6 °C and shipped between 1 and 10 °C;
( 4 ) The blood is held for observation until a significant inspection consistent with the requirements of § 640.5(e) can be made.
[38 FR 32089, Nov. 20, 1973, as amended at 41 FR 4015, Jan. 28, 1976; 42 FR 59878, Nov. 22, 1977; 43 FR 34460, Aug. 4, 1978; 49 FR 15187, Apr. 18, 1984; 49 FR 23834, June 8, 1984; 50 FR 4138, Jan. 29, 1985; 53 FR 116, Jan. 5, 1988; 55 FR 11013, Mar. 26, 1990; 63 FR 16685, Apr. 6, 1998; 64 FR 45371, Aug. 19, 1999; 66 FR 1836, Jan. 10, 2001; 66 FR 31165, June 11, 2001; 66 FR 40889, Aug. 6, 2001; 67 FR 9587, Mar. 4, 2002]
###### Editorial Note on Part 172

#### Editorial Note:

Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

#### § 172.812 Glycine.

The food additive glycine may be safely used for technological purposes in food in accordance with the following prescribed conditions:

(a) The additive meets the specifications of the Food Chemicals Codex, 7th ed. (2010), pp. 457-458, which is incorporated by reference. The Director of the Office of the Federal Register approves this incorporation by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. You may obtain copies from the United States Pharmacopeial Convention, 12601 Twinbrook Pkwy., Rockville, MD 20852 (Internet address *http://www.usp.org*). Copies may be examined at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030 or go to: *http://www.archives.gov/federal-register/cfr/ibr-locations.html.*

(b) The additive is used or intended for use as follows:

| Uses | Limitations |
| --- | --- |
| As a masking agent for the bitter aftertaste of saccharin used in manufactured beverages and beverage bases | Not to exceed 0.2 percent in the finished beverage. |
| As a stabilizer in mono- and diglycerides prepared by the glycerolysis of edible fats or oils | Not to exceed 0.02 percent of the mono- and diglycerides. |

(c) To assure safe use of the additive, in addition to the other information required by the Act:

(1) The labeling of the additive shall bear adequate directions for use of the additive in compliance with the provisions of this section.

(2) The labeling of beverage bases containing the additive shall bear adequate directions for use to provide that beverages prepared therefrom shall contain no more than 0.2 percent glycine.

[42 FR 14491, Mar. 15, 1977, as amended at 49 FR 10105, Mar. 19, 1984; 78 FR 71464, Nov. 29, 2013; 88 FR 17720, Mar. 24, 2023]
[if !vml]>[endif]>

[if !vml]>[endif]>

You havereached the Federal Depository Library Program Electronic Collection (FDLP/EC)Archive. This archive assures ongoing access to publications in the FDLP/EC.Access to publications in the archive is available through GPO's suite ofcataloging and locator services, including the Catalog of U.S. GovernmentPublications (CGP).  Archived copies of publications are retrieved in theevent that publications are no longer available from the original publishingagency site. (Historical purposes)

**Title:** Guide to coping with deployment andcombat stress 

2008,2011,2014

 
SuDoc:D 101.6/5:ST 8����� ����������� 
�Item Number:0325-B (online)
CGP system Number:000616144